J Clin Oncol 2004; 22: 2177–2183. 7 Engels Vorinostat cell line EA, Pfeiffer RM, Goedert JJ et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 2006; 20: 1645–1654. 8 Besson C, Goubar A, Gabarre J et al. Changes in AIDS-related lymphoma

since the era of highly active antiretroviral therapy. Blood 2001; 98: 2339–2344. 9 Franceschi S, Dal Maso L, La Vecchia C. Advances in the epidemiology of HIV-associated non-Hodgkin’s lymphoma and other lymphoid neoplasms. Int J Cancer 1999; 83: 481–485. 10 Mocroft A, Katlama C, Johnson AM et al. AIDS across Europe, 1994–98: the EuroSIDA study. Lancet 2000; 356: 291–296. 11 Matthews GV, Bower M, Mandalia S et al. Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy. Blood 2000; 96: 2730–2734. 12 Thirlwell C, Sarker D, Stebbing J, Bower M. Acquired immunodeficiency syndrome-related lymphoma in the era of highly active antiretroviral therapy. Clin Lymph 2003;

4: 86–92. 13 Stebbing J, Marvin V, Bower M. The evidence-based treatment of AIDS-related non-Hodgkin’s lymphoma. Cancer Treat Rev 2004; 30: 249–253. 14 Boue F, Gabarre J, Gisselbrecht C et al. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin’s lymphoma. J Clin Oncol 2006; 24: IDH signaling pathway 4123–4128. 15 Diamond C, Taylor TH, Im T, Anton-Culver H. Presentation and outcomes of systemic non-Hodgkin’s lymphoma: a comparison between patients with acquired immunodeficiency syndrome (AIDS) treated with highly active antiretroviral therapy and patients without AIDS. Leuk Lymphoma 2006; 47: 1822–1829. 16 Navarro JT, Lloveras N, Ribera JM et al. The prognosis of HIV-infected patients with diffuse large B-cell lymphoma treated with chemotherapy and highly active antiretroviral therapy is similar to that of HIV-negative patients receiving chemotherapy. Haematologica 2005; 90: 704–706.

17 Ribera JM, Oriol A, Morgades M et al. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. B J Haematol 2008; 140: 411–419. 18 Barta SK, Lee JY, Kaplan LD et al. Pooled analysis of AIDS malignancy consortium Selleck Enzalutamide trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma. Cancer 2011; 118: 3977–3983. 19 Sparano JA, Lee JY, Kaplan LD et al. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood 2010; 115: 3008–3016. 20 Castillo JJ, Echenique IA. Rituximab in combination with chemotherapy versus chemotherapy alone in HIV-associated non-Hodgkin lymphoma: a pooled analysis of 15 prospective studies. Am J Hematol 2012; 87: 330–333. 21 Cheson BD, Pfistner B, Juweid ME et al. Revised response criteria for malignant lymphoma.